Skip to main content

Jean Bertoldo

Chemical biologist and Team Leader of the Chemical Biology and Target-Based Drug Design Group at Children's Cancer Institute, Sydney (UNSW).

Nov 9, 2026

21:51
Are you thinking about different lead indications that you preferred one because of your background?
21:57
We are.
21:58
And because this is a question that is raised within the committees we've been to, for example, we've been pitching this to investors and to venture capitalists, angel investors, and showing this to clinicians as well, to people that are in the field and in the industry.
22:16
for quite some time.
22:17
And they always have one concern is our phase one clinical trials, because we know how hard it is to do phase one clinical trials for new investigation drugs in pediatrics.
22:29
So you always need an adult indication at least.
22:33
We've been expanding or studying the mechanism outside of DMG.

6 MINS LATER

28:47
Now, what is your idea of commercialization, partnering, licensing, spinning off? Yeah.
30:06
How did the question challenge your thinking?
30:08
It was a shock.
30:11
in one way it was like a kind of a full realization in the other way because you do tend to have these blind spots as you go along right so the only so only people outside your sphere of outside of your sphere will basically know what your blind spot is so you have to be ready because you might not see the error or you might not see what you're doing wrong but people can see that So one of the things that challenged me a lot was like, oh, okay, I thought I had all figured it out.
30:40
It turns out I don't.
30:41
I didn't back then.
30:43
So we have to basically take the advice, not as them saying, ah, this is not going to go anywhere, or you're not prepared, or you're not good.
30:50
And take it in a way that it's basically to take something that is just an idea or a concept into something that is really...
34:13
Dr. Jean-Bertoldo also left the event with some changes in mind.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.